HM 15211

Drug Profile

HM 15211

Alternative Names: GLP-1/GIP/glucagon triagonist - Hanmi Pharmaceutical; HM15211

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Beijing Hanmi Pharmaceutical; Hanmi Pharmaceutical; Roche
  • Class Peptides
  • Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis; Obesity; Parkinson's disease

Most Recent Events

  • 09 Jul 2017 Preclinical trials in Non-alcoholic steatohepatitis in South Korea (unspecified route)
  • 09 Jun 2017 Preclinical trials in Parkinson's disease in South Korea (unspecified route)
  • 09 Jun 2017 Pharmacodynamics data from a preclinical study in Parkinson's disease presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top